A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: Results of the phase II randomized ABIGAIL study (BO21015)

Journal of Thoracic Oncology

Volumn 9, Issue 6, 2014, Pages 848-855

  Mok, Tony ^a   Gorbunova, Vera ^b   Juhasz, Erzsebet ^c   Szima, Barna ^d   Burdaeva, Olga ^e   Orlov, Sergey ^e   Yu, Chong Jen ^f   Archer, Venice ^g   Hilton, Magalie ^h   Delmar, Paul ^h   Pallaud, Celine ^h   Reck, Martin ⁱ  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^c Orszagos Koranyi Tbc es Pulmonologiai Intezet   (Hungary)

^d Endothelium Study Group   (Hungary)

^e Arkhangelsk Regional Clinical Oncology Dispensary   (Russian Federation)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^g ROCHE PRODUCTS LTD   (United Kingdom)

^h F HOFFMANN LA ROCHE LTD   (Switzerland)

ⁱ GERMAN CENTER FOR LUNG RESEARCH   (Germany)

Author keywords

Bevacizumab; Biomarker; Non small cell lung cancer; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CD31 ANTIGEN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBROBLAST GROWTH FACTOR 2; GEMCITABINE; INTERCELLULAR ADHESION MOLECULE 1; NEUROPILIN; PACLITAXEL; PLACENTAL GROWTH FACTOR; TUMOR MARKER; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; MONOCLONAL ANTIBODY; PLACENTA PROTEIN;

ADVANCED CANCER; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HAZARD RATIO; HUMAN; LEUKOPENIA; LUNG EMBOLISM; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM; ANALOGS AND DERIVATIVES; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; PROSPECTIVE STUDY; SURVIVAL RATE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD31; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; E-SELECTIN; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; LUNG NEOPLASMS; MALE; NEUROPILINS; PACLITAXEL; PREGNANCY PROTEINS; PROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84901595989     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000160     Document Type: Article

References (27)

1. Schiller JH, Harrington D, Belani CP, et al; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non- small-cell lung cancer. N Engl J Med 2002;346:92-98. (Pubitemid 34438899)
2. Scagliotti GV, De Marinis F, Rinaldi M, et al; Italian Lung Cancer Project. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285-4291. (Pubitemid 35266288)
3. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550. (Pubitemid 44917502)
4. Reck M, von Pawel J, Zatloukal P, et al; BO17704 Study Group. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first- line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010;21:1804-1809.
5. Dowlati A, Gray R, Sandler AB, Schiller JH, Johnson DH. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab-An Eastern Cooperative Oncology Group Study. Clin Cancer Res 2008;14:1407-1412. (Pubitemid 351413922)
6. Jayson GC, de Haas S, Delmar P, et al. Evaluation of Plasma VEGFA as a Potential Predictive Pan-tumour Biomarker for Bevacizumab. Stockholm, Sweden: European Multidisciplinary Cancer Conference, 2011.
7. Miles DW, de Haas SL, Dirix L, et al. Plasma Biomarker analyses in the AVADO Phase III Randomized Study of First-line Bevacizumab + Docetaxel in Patients with Human Epidermal Growth Factor Receptor (HER) 2-Negative Metastatic Breast Cancer. San Antonio, TX: San Antonio Breast Cancer Symposium (SABCS), 2010.
8. Jubb AM, Hurwitz HI, Bai W, et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 2006; 24: 217-227. (Pubitemid 46622051)
9. Van Cutsem E, de Haas S, Kang YK, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 2012;30:2119-2127.
10. Van Cutsem E, Jayson G, Dive C, et al. Analysis of Blood Plasma Factors in the AVITA Phase III Randomised Study of Bevacizumab with Gemcitabine- Erlotinib in Patients with Metastatic Pancreatic Cancer. Stockholm, Sweden: European Multidisciplinary Cancer Conference, 2011.
11. Ohta Y, Endo Y, Tanaka M, et al. Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer. Clin Cancer Res 1996; 2: 1411-1416. (Pubitemid 26299442)
12. Volm M, Koomägi R, Mattern J. Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer 1997;74:64-68. (Pubitemid 27157857)
13. Giatromanolaki A, Koukourakis MI, Kakolyris S, et al. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res 1998;4:3017-3024. (Pubitemid 29001476)
14. Fontanini G, Vignati S, Boldrini L, et al. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 1997;3:861-865. (Pubitemid 27252933)
15. Imoto H, Osaki T, Taga S, Ohgami A, Ichiyoshi Y, Yasumoto K. Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg 1998;115:1007-1014. (Pubitemid 28224393)
16. Yuan A, Yu CJ, Shun CT, et al. Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients. Int J Cancer 2005;115:545-555. (Pubitemid 40656711)
17. Nakashima T, Huang CL, Liu D, et al. Expression of vascular endothelial growth factor-A and vascular endothelial growth factor-C as prognostic factors for non-small cell lung cancer. Med Sci Monit 2004;10:BR157-BR165. (Pubitemid 38878774)
18. Huang C, Liu D, Masuya D, et al. Clinical application of biological markers for treatments of resectable non-small-cell lung cancers. Br J Cancer 2005;92:1231-1239. (Pubitemid 40604397)
19. O'Byrne KJ, Koukourakis MI, Giatromanolaki A, et al. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer 2000;82:1427-1432. (Pubitemid 30175909)
20. Han H, Silverman JF, Santucci TS, et al. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol 2001;8:72-79. (Pubitemid 32126827)
21. Oshika Y, Nakamura M, Tokunaga T, et al. Expression of cell-associated isoform of vascular endothelial growth factor 189 and its prognostic relevance in non-small cell lung cancer. Int J Oncol 1998;12:541-544. (Pubitemid 28097280)
22. Han ES, Burger RA, Darcy KM, et al. Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer. Gynecol Oncol 2010;119:484-490.
23. Bremnes RM, Camps C, Sirera R. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 2006;51: 143-158. (Pubitemid 43144358)
24. Leighl N, Reck M, de Haas S, et al. Analysis of biomarkers (BMs) in the AVAIL phase III randomised study of first-line bevacizumab (BV) with cisplatin-gemcitabine (CG) in patients (pts) with non-small cell lung cancer (NSCLC). Eur J Cancer Suppl 2009;7:558.
25. Webb NJ, Bottomley MJ, Watson CJ, Brenchley PE. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin Sci (Lond) 1998;94:395-404. (Pubitemid 28176624)
26. Banks RE, Forbes MA, Kinsey SE, et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 1998;77:956-964. (Pubitemid 28101786)
27. Vermeulen PB, Salven P, Benoy I, Gasparini G, Dirix LY. Blood platelets and serum VEGF in cancer patients. Br J Cancer 1999;79:370-373. (Pubitemid 29002310)